Overview

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
0
Participant gender:
All
Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:

- Current doctor's diagnosis of generalized anxiety disorder

- In need of psychiatric treatment

- Willingness to complete all aspects of the study

Exclusion Criteria:

- Current doctor's diagnosis of major depression

- History of schizophrenia or schizoaffective disorders

- Drug dependence within 2 months prior to study start

For detailed information on eligibility, please contact the study center nearest to you
(see below), or call 1-862-778-8300, or visit the following website:

www.novartisclinicaltrials.com